GELSTAT APPOINTS BUSINESS AND HEALTH CARE LEADER K. JAMES EHLEN, M.D.,
                             TO BOARD OF DIRECTORS

     Former CEO of Allina Health System and CMO of Humana Brings Additional
                Regulatory, Management and Governance Experience

MINNEAPOLIS - September 27, 2004 -- GelStat Corporation (OTCBB: GSAC) today
announced the appointment of K. James Ehlen, M.D. to its board of directors.
Ehlen is a recognized leader in both the business and medical communities. He is
a noted national speaker with a history of leading improvements in financial and
clinical performance through the application of creative, cost-effective health
care solutions.

"I'm enthusiastic about the opportunities for GelStat and its future prospects,
not just in migraine, but in a host of related areas," said Ehlen. "Clearly,
managed health care companies as well as individual consumers are looking for
effective solutions that can improve outcomes and reduce costs. I look forward
to working with my colleagues to achieve the Company's goals, including bringing
increased awareness of GelStat Migraine to the medical establishment."

Stephen Roberts, M.D., chairman and chief executive officer of GelStat said, "We
are exceptionally pleased that Dr. Ehlen has joined our board. His combined
business and medical experience represents a unique and extremely valuable
resource, especially as we see opportunities to position GelStat Migraine and
pending new products as effective and economical treatment options, not only
with consumers directly, but also with health care professionals and managed
care organizations."

Dr. Ehlen is presently CEO of Halleland Health Consulting, a leading health
consulting group with expertise in regulatory and compliance affairs, clinical
and health system integration, strategy and product positioning, and matters of
corporate accountability, governance and ethics. He practiced as an
endocrinologist for 13 years before spending the past 16 years in a series of
executive roles. In 1988 he became chairman and chief executive officer of
Physicians Health Plan that subsequently evolved to Medica. In 1994, as CEO of
Medica, he negotiated a merger with Healthspan to create the Twin Cities' based
integrated health care system, Allina Health System, where he was co-CEO. In
1999, Dr. Ehlen left his position with Allina to become the Chief Medical
Officer (CMO) of Humana, one of the country's largest health maintenance
organizations. He is a past chairman of the Health Forum Board and the VHA
Foundation Board, and is a long-standing member of the American College of
Physician Executives.

ABOUT GELSTAT MIGRAINE

GelStat Migraine is a new over-the-counter (OTC, non-prescription) medication
for acute relief from the pain and associated symptoms of migraine and
migraine-like headaches. Over 90 percent of those with migraine use OTC
medications as part of their treatment arsenal, though in only about 25 percent
of those with moderate to severe headache pain are these older medications
reported to exhibit any effect. Americans purchased over 600 million units of
OTC headache medication last year.

A recent clinical trial showed GelStat Migraine to be effective in 83 percent of
patients, whose migraine pain was either eliminated or arrested at the mild pain
phase by early treatment.




ABOUT GELSTAT CORPORATION

GelStat Corporation is a consumer healthcare company dedicated to the
cost-effective development and marketing of advanced OTC health care products.
Development efforts are focused on large markets where GelStat products can
offer improved efficacy, safety, and/or convenience over existing OTCs. The
Company's initial efforts center on developing products for migraine therapy and
to improve sleep, both multi-billion dollar global markets.

For more information, visit www.GelStat.com


Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statement other than a
statement of historical fact should be considered a forward-looking statement.
Such forward-looking statements are based on the Company's current expectations
and involve known and unknown risks, uncertainties, or other factors which may
cause actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Risks, uncertainties
and assumptions include the possibility that the market for the sale of certain
products, or all products, may not develop as expected, or at all. Readers are
cautioned not to place undue reliance on those forward-looking statements, which
speak only as of the date hereof. The company undertakes no obligation and does
not intend to release publicly any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect
unanticipated events or developments.


Contact:


Media Inquiries:


The Carideo Group, Inc.


Tony Carideo, 612-317-2880


Investor Relations:

Insight Capital

Brock Malky, 724-453-1800




                                       ###